South Korea Pharmaceuticals: key facts
Market size
How much bioreactor capacity does Samsung Biologics have in Songdo?
Samsung Biologics' Songdo plants 1-5 hold 785k L of bioreactor capacity, according to KIRA's 2026 market report (SBL FY25).
Source: SBL FY25, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds
How big is South Korea's domestic pharma market?
Domestic pharma is a slow-growing base of about USD 23 bn in 2025, on a trajectory of about 2.4%, according to KIRA's 2026 market report (Korea Pharma Outlook 2025).
Source: Korea Pharma Outlook 2025, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds
How large were South Korea's pharmaceutical exports in 2025?
South Korea's pharmaceutical exports reached USD 10.4 bn in 2025, up 11.8% year on year, with biologics at 62.6% of the total, according to KIRA's 2026 market report (KPBMA 2026).
Source: KPBMA 2026, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds
Growth
What does KIRA forecast for South Korea's medicine exports in 2027?
KIRA's forecast puts South Korean medicine exports at USD 12.8 bn in 2027, up from USD 10.4 bn in 2025, according to KIRA's 2026 market report (KIRA triangulation of KPBMA and Korea Customs data).
Source: Kira estimates, 2027 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds
What revenue and new orders did Samsung Biologics report in 2025?
Samsung Biologics reached KRW 4.56 trn of revenue and KRW 6 trn of new orders in 2025, according to KIRA's 2026 market report (SBL FY25).
Source: SBL FY25, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds
Trends
How many active clinical trials are running in South Korea?
Active clinical trials in Korea fell to 2,175 in 2025 from 2,307, a warning sign for the pipeline, according to KIRA's 2026 market report.
Source: KIRA research, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds
Key players
How many FDA biosimilar approvals did Korean companies win in 2025?
Korean companies won 5 of 18 US FDA biosimilar approvals in 2025, the most of any country, led by Celltrion and Samsung Bioepis, according to KIRA's 2026 market report (MDToday 2026).
Source: MDToday 2026, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds
Regulation
What does the third five-year bio plan target by 2030?
The third five-year bio plan targets doubled bio exports and three blockbuster drugs by 2030, according to KIRA's 2026 market report.
Source: KIRA research, 2030 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds
How does the BIOSECURE Act affect Korean contract manufacturers?
The BIOSECURE Act, signed into the FY26 NDAA, redirects US demand that Chinese CDMOs lose to Korean plants, according to KIRA's 2026 market report (Lawtimes 2026).
Source: Lawtimes 2026, 2026 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds
Who's who
active pharmaceutical ingredients
27 companies in BizDirect Asia's database. Supplier list · Manufacturer list · Distributor list
- SI Group
- 대정화금
- 경동제약
- 한미정밀화학
- 하나제약
- 코오롱생명과학 (Seoul)
- Chemtros (Gyeonggi)
- 경보제약
- Angene Chemical
- 폴라리스그룹 (Jeonbuk)
Top regions: Gyeonggi (7), Seoul (3), Jeju (1), Jeonbuk (1)
pharmaceutical raw materials
8 companies in BizDirect Asia's database. Distributor list
- 풍림무약 (Seoul)
- 경방신약
- 원풍약품상사 (Seoul)
- JK SCIENCE
- 두한바이오
- SSR Chemicals (Seoul)
- 코센트 (Seoul)
- Snet company
Top regions: Seoul (4)
Company data: BizDirect Asia (sister company)